GSTM3 and cancer: Particularly, GSTM3 has been shown to be dysregulated in various cancers such as renal cancer (11), prostate carcinoma (12), breast carcinoma (13), hepatic carcinoma (14), colorectal carcinoma (15), and cervical malignancy (16).